---
title: "Allarity Therapeutics wins USPTO notice of allowance for stenoparib DRP patent, exclusivity through 2039"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284382840.md"
description: "Allarity Therapeutics has received a USPTO Notice of Allowance for its stenoparib DRP® companion diagnostic patent, expected to be granted within three months. This patent will provide exclusivity for stenoparib until 2039 when used with the DRP test. The allowed claims focus on methods to predict patient benefit through gene expression profiles. Allarity also holds related patents in Europe and Australia, along with other global DRP patents and pending applications."
datetime: "2026-04-28T12:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284382840.md)
  - [en](https://longbridge.com/en/news/284382840.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284382840.md)
---

# Allarity Therapeutics wins USPTO notice of allowance for stenoparib DRP patent, exclusivity through 2039

**Allarity Therapeutics received a USPTO Notice of Allowance for its stenoparib DRP® companion diagnostic, expected to be granted within three months and provide exclusivity into 2039 when used with stenoparib.**

**Key Highlights:**

-   USPTO issued a Notice of Allowance for Allarity’s stenoparib DRP® companion diagnostic patent application.
-   Patent is expected to be formally granted within three months, subject to standard administrative procedures.
-   If granted, patent would provide exclusivity at least into 2039 for stenoparib when used with the DRP test.
-   Allowed claims cover methods to predict benefit and select patients via gene expression profiles for stenoparib treatment.
-   Allarity already holds related patents in Europe and Australia and has other DRP patents and pending applications globally.

Original SEC Filing: Allarity Therapeutics, Inc. \[ ALLR \] - 8-K - Apr. 28, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Allarity Therapeutics Q1 net loss per share narrows](https://longbridge.com/en/news/286612460.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Guardant Health Says US FDA Approved Liquid Biopsy Test](https://longbridge.com/en/news/287069625.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)